Ekf Diagnostics Share Discussion Threads

[tongosti] 07/4/2022 18:32

True that but you are now talking about something different in that you are talking about the way you decide to "source" opportunities in the markets rather than tour your entry / exit positions (which are always aligned (long or short) if one is to turn a profit) Re commods - the entire complex. Check out SALL - a very comprehensive ETP giving you inverse exposure to the whole basket. Good luck.

[cisk] 07/4/2022 18:21

I mean the market does not always price stocks correctly. It's driven by supply & demand, and irrational at times.

Which commodities?

[tongosti] 07/4/2022 18:07

And yea been having a short for ages on ekf (otherwise why would I appear on this board). small position though - not out of want but out of circumstances. One can't shift a proper size on the short side with such a minnow like ekf (this doesn't hold true on the long side of one builds up a position over several days).

[tongosti] 07/4/2022 17:40

Not sure what you are trying to say but Mr Market is always right. FACT not fiction (one only makes money by being on the right side (long or short) of him - please let me know if you may have discovered another way , keen to learn). Don’t take my word for it. Take Paul Tudor Jones’ / Jim Simons’s / Stan Druckenmller’s (or Jesse Livermore’s if you care to go a bit back in history of market giants). Look them up.

No stock exposure at the moment. Gradually building a short commodities position whilst biding my time to go short rates (when stars align).

[cisk] 07/4/2022 16:53

Tong, you are correct and I walked back my comment at the time. Investing isn't personal, we may differ in approaches and tone but that's what makes life interesting.

I do disagree with your view on Mr Market though. He's not the judge of all, not by a long stretch. And it implies the market always gets it right -all of the time - which never happens.

Anyway, did you short EKF down from the 80s? And where else are you casting your net?

As for Wan, I appreciate his wider posts on the subject matter, and understand his enthusiasm, but assess objectively.

[cisk] 07/4/2022 16:08

Tong, congratulations on your clairvoyance. I'm sure I stand with other posters on this board in appreciation.

[tongosti] 06/4/2022 16:48

High volumes breaking down below 40. Am sure wan will find a fresh of reasons to be cheerful tomorrow whilst all previous paper profits evaporate

[tongosti] 06/4/2022 14:44

Hope you're feeling much better pal. Explanation in two sentences: 1. there were no disbelievers left meaning the business has been having to catch-up with sky high expectations of tree growing to the sky 2. C19 business related boost was priced in way before the vaccine news broke out.

[nurdin] 06/4/2022 13:52

Having been absent from the market for some time due to health reasons I was shocked to see the collapse in the share price here from 80pish on my return.Cant see any news that would justify such a fall.Can anyone offer an explanation? Many thanks.

[wan] 06/4/2022 07:52

I note Yourgene are set to layout their roadmap and growth plans -

06/04/2022 7:01am
RNS Non-Regulatory

Yourgene Health PLC

06 April 2022

Yourgene Health plc

("Yourgene" or the "Company")

Capital Markets Day

Manchester, UK - 6 April 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces it will be holding a Capital Markets Day for investors on Tuesday 26 April 2022.

The event will provide investors with a compelling opportunity to hear more from other senior members of the management team about the roadmap and growth plans for certain products and services, both in North America and internationally, as well as perspectives on the dynamics within the molecular diagnostics market and the scope for growing the Company's genomic services business.

An opening and closing address will be given by CEO, Lyn Rees who will provide an overview of the Company and where it is currently positioned. The event will also feature presentations by:

-- Dr Rachel Shelmerdine, Product Management
-- Scott Sargent, Vice President, Sales Americas
-- Bhavika Patel, Technical Director, Yourgene Genomic Services
-- Jonathan Seaton, Non-Executive Director, Yourgene Health plc
The event will be repeated in the City of London at 4pm for non-institutional investors and will be followed by light refreshments and an opportunity to talk to the senior management further.

[tongosti] 05/4/2022 13:29

Wan - if you have anything to say re demand supply for shares (the ultimate variable that matters) let us know pal. All ears.

[drew lonmenob] 05/4/2022 12:53

just repaying the compliment dear chap wrongun

[tongosti] 05/4/2022 12:46

Been wrong indeed Bobby doughnut from 80p down on here. Enjoying stalking me on these boards?

[tongosti] 05/4/2022 12:38

On the three day timeframe you have increasing volumes on the way down. In other words, the selling pressure far outweighs the other side of the trade. Hence the balance of odds favours the short side, as of now.

[tongosti] 05/4/2022 12:26

You got it wrong. Supply and demand for shares is what I was talking about. As in any other asset prices, interaction of demand and supply dictates what one gets for labour / houses / commodities / whatever. In the stock market it is SHARES. If you understood what drives imbalances in such an equation you would see what I see. Very funny supply and demand are crucial in economics but somehow folks have convinced themselves understanding it properly in finance is redundant?! Go figure what passes for common sense these days.

[wan] 05/4/2022 10:48

Staying with supply and demand as ultimately making or losing hard cash.

On the one hand EKF expects COVID-19 testing to continue, but for COVID-related revenues to materially reduce in 2022. Clearly COVID-19 had a very negative impact on other areas of the healthcare market in which EKF operate.

So, all things being equal, other healthcare markets will continue to significantly improve (and grow) as demonstrated by EKF Results detailing the performance of the core businesses segments.

In other words, there is a two way street in operation, albeit for the time being there is a speed restriction on our side of the street as EKF execute on the Growth Strategy and retransition to growth, which includes addressing opportunities in new markets and the distribution of new products, with EKF ultimately increasing their exposure to various growth areas of the healthcare and life science markets.

Put another way, EKF itself is not remotely stagnating, which is presumably why EKF's broker, Singer Capital Markets, viewed any share price weakness as a strong buying opportunity.

[tongosti] 05/4/2022 09:26

While Wan is getting ready to uncork the bubbly (for a change), the market is on the verge of a breakdown. If we touch 40, then 33 will be reached in the blink of an eye, in all likelihood. It's a very funny business where folks choose to ignore the number 1 fundamental - the interaction of demand and supply which ultimately makes or loses one cold hard cash!

[wan] 05/4/2022 09:13

Buywell...5,950,000 to be precise!

I duly noted SBI's results.

There is an important and fundamental difference regarding the buyback. SBI's recent acquisition, along with future earnout payments are all payable in cash. Whereas EKF's recent acquisition was satisfied by the issue of new ordinary shares at 80p+ to the value of £10mn. A similar amount of shares are now being bought back at 40p+ and held in treasury. And as my post 2612 above alludes to, the treasury shares could potentially be utilised to satisfy the ADL earnouts.

And wouldn't it be good business if the shares at the various earnout anniversaries are materially higher than current buybacks, potentially meaning in my book that the treasury shares were even better value (to EKF and its investors), bearing in mind that the price per share issued to satisfy any earnout payments will be calculated using the average mid-market closing price of EKF’s shares for the five working days immediately preceding the issuance date of such shares.

Obviously we don't know where the share price might be come October (1st ADL anniversary), but we know there will be news flow between now and October and we know there are various developments in the pipeline, including further execution on the Growth Strategy.

So, for the purpose of an example and perhaps only for those with a positive and longer term view on EKF. Imagine a scenario where earnouts are calculated at an average mid-market closing price of EKF’s shares at 60p+ (being conservative!) when EKF are holding shares in treasury bought at 40p+.

Food for thought!

[tongosti] 05/4/2022 08:43

Mr Market ain't impressed.

[buywell2] 05/4/2022 08:10

6M buybacks and only another 3M left is that not correct

Then quite a long wait for the next tranche if it gets the nod

Interestingly SBI have not announced an initial/interim buyback program like EKF

What say you wan ?

05 Apr 2022 7:00 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares
04 Apr 2022 7:00 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares
01 Apr 2022 7:00 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares
31 Mar 2022 7:00 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares
30 Mar 2022 7:00 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Purchase of Own Shares
29 Mar 2022 7:01 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Share Buyback Programme
7:00 am
RNS
Factsheet EKF Diagnostics Hldg (EKF) Final Results